Chief Physician of the Department of Melanoma and Sarcoma Medical Oncology, Peking University Cancer Hospital; Associate Professor and Doctoral Supervisor at Peking University. Ph.D. in Oncology from Peking University, Senior Visiting Scholar at Moffitt Cancer Center, USA. Recipient of the National High-Level Young Talent Program and Peking University Boya Young Scholar. Specializes in the clinical diagnosis and treatment of melanoma, sarcoma, and urological tumors, with particular expertise in precision diagnosis and translational research of melanoma. As a core member, initiated/participated in multiple prospective clinical studies on melanoma that have changed clinical practice. In recent years, as corresponding/first author (including co-authors), published 15 SCI papers in authoritative journals such as Ann Oncol (2017, 2022, 2024), JAMA Oncol, Clin Cancer Res, Int J Radiat Oncol, and Eur J Cancer. Invited to deliver three oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. Research findings have been adopted by seven domestic and international melanoma guidelines, including those from the U.S. NCCN, ASCO, and SITC. Authored three editions of nine versions of melanoma diagnosis and treatment guidelines for the National Health Commission, Chinese Society of Clinical Oncology, and Chinese Anti-Cancer Association. Led 10 national/provincial-level scientific research projects. Recognized with honors such as Beijing Outstanding Young Talent, Beijing Hospital Management Center Young Seedling Talent, Peking University Clinical Scientist (Extended Support), First CSCO "35 under 35 Most Promising Young Oncologist," and Peking University Health Science Center "Outstanding Specialist Training Instructor." Also serves as Secretary-General of the Malignant Melanoma Committee of the Chinese Society of Clinical Oncology (CSCO), Member of the Melanoma Quality Control Committee of the National Cancer Quality Control Center, Member of the CSCO Cardio-Oncology Committee, Member of the CSCO Geriatric Oncology Prevention and Treatment Committee, and Member of the Youth Innovation Alliance of the Integrated Oncology Branch of the Chinese Anti-Cancer Association (CACA).